Particle News: Latest National Institute for Health and Care Excellence news

Bristol Myers Sets U.K. Price for New Schizophrenia Drug Equal to U.S., Threatens to Pull Product

The company will seek U.K. approval within weeks, tying a planned 2026 launch to acceptance of a $1,850 monthly list price.

8 ARTICLES

3w ago

Large UK Studies Validate Age-Adjusted CA125 Tool for Earlier Ovarian Cancer Detection

25 ARTICLES

3w ago

GSK Pledges $30 Billion U.S. Investment as UK Drug-Pricing Standoff Drives Pullbacks

10 ARTICLES

last mo.

Pilot RCT Signals Faster IVF Conception for Women 35–42 Using PGT-A

3 ARTICLES

last mo.

Streeting Criticizes Drug Firms After UK Drug-Pricing Talks Collapse

12 ARTICLES

last mo.

NICE Recommends Padcev–Keytruda as First-Line NHS Treatment for Advanced Bladder Cancer

3 ARTICLES

last mo.

FOI Reveals Postcode Lottery in Prostate Cancer Care as Charities Demand NICE Guideline Update

3 ARTICLES

2mo ago

Calls Grow for Stricter Cancer Trial Safety After Fatal Immunotherapy Case

21 ARTICLES

2mo ago

NICE Requires Yearlong Follow-Up for NHS Weight-Loss Injection Patients

6 ARTICLES

2mo ago

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

10 ARTICLES

2mo ago

Researchers Propose Widening Preventive Mastectomy Access to Avert 6,500 UK Breast Cancer Cases a Year

7 ARTICLES

2mo ago

NICE Approves First Under-the-Tongue Birch Pollen Immunotherapy Tablet for Severe Hay Fever

6 ARTICLES

2mo ago

NICE Approves Alyftrek, Extending Modulator Treatment to 95% of Cystic Fibrosis Patients

3 ARTICLES

3mo ago

Coroner Blames Unattended Delivery for Newborn’s Death and Orders National Review

5 ARTICLES

3mo ago

UK Regulator Approves First Non-Hormonal Pill for Menopausal Hot Flushes

Particle.news

National Institute for Health and Care Excellence

Non-departmental public body

Bristol Myers Sets U.K. Price for New Schizophrenia Drug Equal to U.S., Threatens to Pull Product

Large UK Studies Validate Age-Adjusted CA125 Tool for Earlier Ovarian Cancer Detection

GSK Pledges $30 Billion U.S. Investment as UK Drug-Pricing Standoff Drives Pullbacks

Pilot RCT Signals Faster IVF Conception for Women 35–42 Using PGT-A

Streeting Criticizes Drug Firms After UK Drug-Pricing Talks Collapse

NICE Recommends Padcev–Keytruda as First-Line NHS Treatment for Advanced Bladder Cancer

BMJ Experts Warn Against Commercial Menopause Testing and Compounded Hormones

NICE Backs Six Digital Cardiac Rehab Tools for NHS Trial Use

NICE Unveils Draft Overhaul of Type 2 Diabetes Care in England

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

Never miss stories about

National Institute for Health and Care Excellence

‘Murder Wasps’ Set to Swarm Across UK as Call-Outs Surge

FOI Reveals Postcode Lottery in Prostate Cancer Care as Charities Demand NICE Guideline Update

Calls Grow for Stricter Cancer Trial Safety After Fatal Immunotherapy Case

NICE Requires Yearlong Follow-Up for NHS Weight-Loss Injection Patients

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

Researchers Propose Widening Preventive Mastectomy Access to Avert 6,500 UK Breast Cancer Cases a Year

NICE Approves First Under-the-Tongue Birch Pollen Immunotherapy Tablet for Severe Hay Fever

NICE Approves Alyftrek, Extending Modulator Treatment to 95% of Cystic Fibrosis Patients

Coroner Blames Unattended Delivery for Newborn’s Death and Orders National Review

UK Regulator Approves First Non-Hormonal Pill for Menopausal Hot Flushes

Never miss stories about

National Institute for Health and Care Excellence